Compare ROCK & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROCK | SANA |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | 2221 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1996 | 2021 |
| Metric | ROCK | SANA |
|---|---|---|
| Price | $37.45 | $3.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.80 |
| AVG Volume (30 Days) | 326.8K | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,135,501,000.00 | N/A |
| Revenue This Year | $41.26 | N/A |
| Revenue Next Year | $20.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.56 | $2.10 |
| 52 Week High | $75.08 | $6.55 |
| Indicator | ROCK | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 40.24 |
| Support Level | $37.77 | $2.97 |
| Resistance Level | $40.84 | $3.43 |
| Average True Range (ATR) | 1.73 | 0.18 |
| MACD | 0.16 | -0.03 |
| Stochastic Oscillator | 62.64 | 16.67 |
Gibraltar Industries Inc manufactures and provides products and services for the Renewable energy, Residential, Agtech, and Infrastructure markets. The Renewable Segment is engaged in designing, engineering, manufacturing, and installing solar racking and electrical balance systems. Agtech Segment provides growing and processing solutions including the designing, engineering, manufacturing, full-scope construction, maintenance, and support of greenhouses and indoor growing operations, and botanical extraction systems. It derives key revenue from the Residential segment which offers roof and foundation ventilation products, single point and centralized mail systems electronic package solutions, and Retractable awnings and gutter guards, among other products.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.